Precision Biosciences Inc (NASDAQ:DTIL) has a beta value of 1.62 and has seen 99538.0 shares traded in the last trading session. The company, currently valued at $21.40M, closed the last trade at $5.27 per share which meant it gained $0.21 on the day or 4.15% during that session. The DTIL stock price is -268.69% off its 52-week high price of $19.43 and 31.5% above the 52-week low of $3.61. If we look at the company’s 10-day average daily trading volume, we find that it stood at 89910.0 shares traded. The 3-month trading volume is 483.91K shares.
The consensus among analysts is that Precision Biosciences Inc (DTIL) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -2.94.
Precision Biosciences Inc (NASDAQ:DTIL) trade information
Sporting 4.15% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the DTIL stock price touched $5.27 or saw a rise of 2.59%. Year-to-date, Precision Biosciences Inc shares have moved 38.32%, while the 5-day performance has seen it change 12.13%. Over the past 30 days, the shares of Precision Biosciences Inc (NASDAQ:DTIL) have changed 0.19%. Short interest in the company has seen 0.76 million shares shorted with days to cover at 0.64.
Wall Street analysts have a consensus price target for the stock at $15.5, which means that the shares’ value could jump 66.0% from current levels. The projected low price target is $1.0 while the price target rests at a high of $30.0. In that case, then, we find that the current price level is -469.26% off the targeted high while a plunge would see the stock lose 81.02% from current levels.
Precision Biosciences Inc (DTIL) estimates and forecasts
The company’s shares have lost -41.18% over the past 6 months. Revenue growth from the last financial year stood is estimated to be 48.38%.
4 analysts offering their estimates for the company have set an average revenue estimate of 4.28M for the current quarter. 1 have an estimated revenue figure of 10M for the next ending quarter. Year-ago sales stood 7.04M and 17.58M respectively for this quarter and the next, and analysts expect sales will shrink by -39.26% for the current quarter and 48.38% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 7.97% over the past 5 years. Earnings growth for 2025 is a modest 100.42% while over the next 5 years, the company’s earnings are expected to increase by 38.09%.
DTIL Dividends
Precision Biosciences Inc is expected to release its next earnings report in March this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Precision Biosciences Inc (NASDAQ:DTIL)’s Major holders
Insiders own 6.40% of the company shares, while shares held by institutions stand at 50.49% with a share float percentage of 53.94%. Investors are also buoyed by the number of investors in a company, with Precision Biosciences Inc having a total of 69.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of Sep 30, 2024 , the former fund manager holds about 2.28% shares in the company for having 174.93 shares of worth $0.92 million while later fund manager owns 39.95 shares of worth $0.21 million as of Sep 30, 2024 , which makes it owner of about 0.52% of company’s outstanding stock.
